BENCHMARKS
the expression levels of soluble protein between the Vertiga screening trials and large-scale growth conditions (Table 1) . In contrast, without the Vertiga shaker, the correlation between microliter-and milliliter-(and liter) scale expression is much lower (data not shown). The two proteins that behaved differently between micro-and macro-expression, BH0832 (GenBank ® accession no. 10173447) and AGR_L_2357p (accession no. 15159665), did so in only one of the two experiments; in the second, the micro-and macro-expression behavior was identical for both proteins (Table  1) . Finally, eukaryotic proteins from Saccharomyces cerevisiae and viral proteins from the Severe Acute Respiratory Syndrome (SARS) virus have also been successfully micro-expressed in E. coli using this device.
These results demonstrate that the microliter-scale expression protocol developed using the Vertiga vertical shaker can be used to accurately identify proteins that will express solubly in larger-scale fermentation conditions. Moreover, the results from these screens can be used to assess the solubility and expected protein yield for each potential protein target for both native and labeled E. coli recombinant expression. Future developments include using material directly from microliter-scale expression for biophysical analysis, including nanovolume crystallization (10) and other biophysical techniques currently being miniaturized.
Robust expression of transgenes in MCF-7 breast cancer cells is expression vector-dependent
Paul Winnard, Jr., Yelena Mironchik, and Venu Raman
The Johns Hopkins University, Baltimore, MD, USA BioTechniques 37:370-374 (September 2004) We are reporting that the in vivo protein expression in mammalian MCF-7 breast cancer cells can be highly dependent on the type of commercially available expression vectors used. Figure 1 is a representation of the vector backbones used and indicates the position of our genes of interest (denoted Insert) relative to the cytomegalovirus (CMV) promoter and simian virus 40 (SV40) poly(A) signal sequence in a pCMVTag4A vector (Stratagene, La Jolla, CA, USA), which resulted in an in-frame fusion at the 3′ end with a FLAG ® epitope sequence. Figure 1 also depicts the placement of these FLAG-tagged genes (including a TGA stop codon) into a pEF-1α-His/Myc vector (Invitrogen, Carlsbad, CA, USA) and their relative positions with respect to the elongation factor-1α (EF-1α) promoter and bovine growth hormone (BGH) poly(A). Thus, except for the vector backbones, both fusion gene construct sequences were identical in the two vector systems. Sequencing analyses proved that each gene sequence was correct and in-frame with the FLAG sequence and stop codon. All plasmids were prepared using the Qiagen ® Plasmid Midi Kits (Qiagen, Valencia, CA, USA). Initial transient BENCHMARKS transfection experiments indicated that little or no transgene-encoded proteins were made in MCF-7 cells transfected with the Stratagene vector constructs. In order to eliminate the possibility that the Stratagene-based plasmid preparations were contaminated with an inhibitory substance(s) or had some mutations, we performed a second round of experiments. Stratagene-based plasmid constructs were grown, put through two rounds of plasmid purification (260:280 = 1.75 to 1.80), and once again sequenced, which eliminated the questions about any acquired mutations. In order to semiquantitatively evaluate transgene expression, transient transfection experiments included either the Renilla luciferase or enhanced green fluorescent protein (EGFP) reporter expression vectors. Figure 2 shows a representative immunoblot (out of three that were semiquantitative blots and seven nonquantified blots). Figure 3 illustrates that the CMV promoter can generate protein expression levels that are only about two times less than those generated by the EF-1α promoter when it is within the context of the EF-1α-based vector backbone. Taken together, these results indicate that vector-driven in vivo protein expression in MCF-7 cells can be vector-dependent. The cases tested here, Invitrogen's pEF-1α-His/Myc vector versus Stratagene's pCMVTag4A vector, show that the majority of the loss of protein expression Figure 1 . Illustration of the mammalian expression vector constructs used in this study. Locations of each vector's major regulatory components along with the genes of choice (labeled Insert) are depicted. Differences include promoters and polyadenylation signal sequences as well as the placement of the ColE1 ori sequences and vector size. Genes were inserted into Stratagene's pCMVTag4A vector in-frame with a FLAG epitope sequence. FLAG-tagged genes along with TGA stop codons were excised from the pCMVTag4A-Flag vectors with SacII and KpnI digestion, blunt-ended (T4 DNA polymerase), and ligated into the EcoRV site of Invitrogen's pEF-1α-His/Myc vector, creating the pEF-1α-Flag-stop constructs. MCS, multiple cloning site; CMV, cytomegalovirus; TK, thymidine kinase; EF-1α, elongation factor-1α; SV40, simian virus 40; pA, polyadenylation; BGH, bovine growth hormone. The lefthand lane shows protein expression from a vector prepared from the same pEF-1α-Flag-Stop vector construct where the elongation factor-1α (EF-1α) promoter has been replaced by the cytomegalovirus (CMV) promoter. This blot indicates that, even within the context of an identical vector backbone, the EF-1α promoter gives higher protein expression (approximately 2-fold higher; n = 2) than the CMV promoter. Protein loading was normalized to Renilla luciferase luminescence.
BENCHMARKS from pCMVTag4A-based constructs can be attributed to vector components or an arrangement of vector components in Stratagene's vector backbone other than its promoter. However, under the conditions used within this study, the EF-1α promoter consistently produced higher levels of protein.
A variety of reasons could explain these results although most have not been systematically studied by us. Mammalian expression vector development (1,2) has gone hand in hand with a continuous effort to increase the efficacy of these vectors (3) (4) (5) (6) . Optimal promoter activity has often been the focus of such design efforts (e.g., Reference 5). Throughout continued testing, the CMV promoter has been proven to give robust in vivo expression of an investigator's choice of transgenes (7, 8) . However, certain limitations with the use of the CMV promoter have also been reported. For example, it has been shown that the CMV promoter can be silenced (9) . In addition, the CMV promoter can be down-regulated by wild-type p53 tumor suppressor protein (10) . An alternative promoter that has come into routine use is the EF-1α promoter (11) (12) (13) . However, comparisons of the capabilities of the CMV versus the EF-1α promoter to drive expression of mammalian transgenes have produced equivocal results (e.g., compare Reference 8 and Reference 13). For example, Kim et al. (14) have recently reported that generally the EF-1α promoter is superior in driving transgene expression as compared to the CMV promoter due to the inclusion of the first intron of the EF-1α gene within the context of the promoter. Evidence is also building that the EF-1α promoter may have advantages over the CMV promoter with respect to persistent transgene expression in stable clones (11, 13) . Another component of vector engineering that has come under study has been the choice of poly(A) signal sequence (15, 16 ). Yet, as with promoter comparisons, comparisons of the SV40 poly(A) sequence versus the BGH poly(A) sequence can produce equivocal results (15, 16) . These reports and others (e.g., Reference 17) indicate that many factors can contribute to the regulation of transgene expression in mammalian cells. Thus, it is prudent to analyze more than one promoter and backbone sequence for its ability to modulate high protein expression within a given cell type or tissue. This is important if an efficient evaluation of the overexpressed protein's in vivo function(s) as well as its impact on cellular physiology is to be made. On the other hand, vector-driven synthesis of suboptimal or nondetectable quantities of protein makes an evaluation of the protein's effect(s) on cellular function a dubious and expensive task. Such considerations may be particularly pertinent in the context of cancer cells, such as MCF-7s, because dysregulation of genetic information is the norm in such cells and is likely to affect protein synthesis.
